Sign up to our newsletter Subscribe
An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Sign up to our newsletter Subscribe
For information on OHE at ISPOR Europe please see earlier posts: OHE at ISPOR Europe 1 and OHE at ISPOR Europe 2. Does the choice of health state comparator or ordering of dimensions matter when valuing EQ-5D-5L? OHE’s Koonal…
MCDA for valuing orphan medicines. A pilot study
OHE’s Martina Garau delivered a presentation at the 12th Conference of the Polish Pharmacoeconomics Society (part of the ISPOR Poland chapter) in Warsaw on 4th December 2014. Martina’s presentation included an introduction on the use of multiple criteria decision analysis (MCDA) in health care decision making and a discussion of the method and finding of a practical application of MCDA to assess the value of orphan medicines.
The results of the pilot study were published in Value in Health (http://www.valueinhealthjournal.com/article/S1098-3015%2813%2904356-8/abstract)
An earlier version of the article was published as an OHE research paper and can accessed at
https://www.ohe.org/publications/multi-criteria-decision-analysis-value-orphan-medicines
For additional information please contact Martina Garau at OHE
An error has occurred, please try again later.